9 AI News Updates Investors Should Not Miss

8. Tevogen Bio Holdings Inc. (NASDAQ:TVGN)

Number of Hedge Fund Holders: 12

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T-cell therapies for treating infectious diseases, cancers, and neurological disorders. The company also leverages artificial intelligence through the Tevogen.AI initiative to accelerate drug discovery and development. The company confirmed on March 3 that it had secured the remaining $8 million non-dilutive funding from KRHP LLC (“Grantor”).

The $8 million funding that completes the $10 million total grant, comes on the heels of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) achieving significant milestones on its AI initiatives under Tevogen.AI. The validation affirms meaningful technological development progress as the company accelerates PredicTcell Platform advancement. Tevogen’s progress in artificial intelligence through its AI division represents a strategic diversification beyond traditional biotech development. Microsoft’s partnership provides critical technical infrastructure and potential enterprise-level validation, significantly enhancing AI development capabilities.

“Tevogen Bio’s disciplined business model is designed for long-term success without reliance on excessive capital raises or shareholder dilution. This additional $8 million in non-dilutive funding reinforces the efficiency and sustainability of our approach, which we believe must be the new standard in biotech,” commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio.